MSD ties up with 5 Indian pharma majors for supply of oral COVID-19 drug Molnupiravir
The Hindu
MSD has signed agreements with Cipla Ltd., Dr. Reddy’s Laboratories, Emcure Pharmaceuticals Ltd., Hetero Labs Ltd. and Sun Pharmaceutical Industries Ltd
MSD Pharmaceuticals Pvt. Ltd., a wholly-owned subsidiary of Merck Sharp & Dohme and known as Merck & Co., Inc., has entered into non-exclusive voluntary licensing agreements with five top Indian generic manufacturers for supply of molnupiravir, an investigational oral antiviral agent currently being studied in a Phase-3 trial for the treatment of non-hospitalised patients with confirmed COVID-19, in India. MSD which is developing molnupiravir in collaboration with Ridgeback Biotherapeutics has entered into these agreements to accelerate availability of molnupiravir in India and in other low- and middle-income countries (LMICs) following approvals or emergency authorisation by local regulatory agencies, it said “These agreements, toward which we have been working as we have been studying molnupiravir, will help to accelerate access to molnupiravir in India and around the world,” said Kenneth C. Frazier, chairman and CEO, Merck & Co., Inc., U.S.More Related News
Air India has signed an agreement with Bengaluru Airport City Limited (BACL), a subsidiary of Bangalore International Airport Limited (BIAL), to develop a built-to-suit facility for the AME program that will feature modern classrooms, well-equipped laboratories for practical training and a team of qualified trainers.